Claims for Patent: 10,576,160

Summary for Patent: 10,576,160

Title:	Nucleophilic catalysts for oxime linkage
Abstract:	The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
Inventor(s):	Siekmann; Juergen (Vienna, AT), Haider; Stefan (Prinzersdorf, AT), Rottensteiner; Hanspeter (Vienna, AT), Turecek; Peter (Klosterneuburg, AT)
Assignee:	Baxalta Incorporated (Bannockburn, IL) Baxalta GmbH (Zug, CH)
Application Number:	15/644,129
Patent Claims:	1. A method of conjugating a PSA containing an active aminooxy group to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated PSA under conditions that allow conjugation; wherein the PSA containing an active aminooxy group is prepared by a method comprising: a) incubating a solution comprising an oxidized PSA with an aminooxy linker comprising an active aminooxy group under conditions that allow the formation of a stable oxime linkage between the oxidized PSA and the activated aminooxy linker, said conditions comprising a time period between about 1 minute and about 24 hours; a temperature between about 2.degree. C. and about 10.degree. C.; in the presence or absence of light, and with or without stirring; thereby forming a PSA containing an active aminooxy group; and b) purifying the PSA containing an active aminooxy group by a method selected from the group consisting of chromatography, filtration, dialysis, and precipitation or combinations thereof, at a temperature between about 2.degree. C. and about 8.degree. C.; wherein said carbohydrate moiety is oxidized by incubation with a buffer comprising an oxidizing agent sodium periodate (NaIO.sub.4), or lead tetraacetate (Pb(OAc).sub.4); wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the PSA; and wherein said oxime linkage formation is catalyzed by m-toluidine. 2. The method according to claim 1 wherein the solution comprising the oxidized PSA and the aminooxy linker comprising an active aminooxy group is incubated at 4.degree. C. for 1 h in the absence of light with stirring. 3. The method according to claim 2 wherein the PSA containing an active aminooxy group is purified by anion exchange chromatography at a temperature of 4.degree. C. 4. The method according to claim 2 wherein the PSA is oxidized by incubation with NaIO.sub.4. 5. The method according to claim 1 wherein the therapeutic protein selected from the group consisting of Factor IX (FIX), a therapeutic protein that has the same biological activity of FIX, Factor VIII (F VIII), a therapeutic protein that has the same biological activity of FVIII, Factor VIIa (FVIIa), a therapeutic protein that has the same biological activity of FVIIa, Von Willebrand Factor (VWF), Factor V (FV), Factor X (FX), Factor XI (FXI), Factor XII (FXII), thrombin (FII), protein C, protein 5, tPA, PAM-, tissue factor (TF), ADAMTS 13 protease, IL-i alpha, IL-1 beta, IL,-2, IL,-3, IL,-4, TL-5, TL-6, IL-1 1, colony stimulating factor-1 (CSF-1), M-CSF, SCF, GM-CSF, granulocyte colony stimulating factor (G-CSF), EPO, interferon-alpha (IFN-alpha), consensus interferon, IFN-beta, IFN-gamma, IFN-omega, IL,-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, TL-21, IL-22, IL-23, IL-24, IL-31, TL-32 alpha, TL-33, thrombopoietin (TPO), Ang-1, Ang-2, Ang-4, Ang-Y, angiopoietin-like polypeptide 1 (ANGPTLI), angiopoietin-like polypeptide 2 (ANGPTL2), angiopoietin-like polypeptide 3 (ANGPTL3), angiopoietin-like polypeptide 4 (ANGPTL4), angiopoietin-like polypeptide 5 (ANGPTL5), angiopoietin-like polypeptide 6 (ANGPTL6), angiopoietin-like polypeptide 7 (ANGPTL7), vitronectin, vascular endothelial growth factor (VEGF), angiogenin, activin A, activin B, activin C, bone morphogenic protein-i, bone morphogenic protein-2, bone morphogenic protein-3, bone morphogenic protein-4, bone morphogenic protein-5, bone morphogenic protein-6, bone morphogenic protein-7, bone morphogenic protein-8, bone morphogenic protein-9, bone morphogenic protein-i0, bone morphogenic protein-i1i, bone morphogenic protein-i2, bone morphogenic protein-i3, bone morphogenic protein-i4, bone morphogenic protein-i5, bone morphogenic protein receptor IA, bone morphogenic protein receptor TB, bone morphogenic protein receptor II, brain derived neurotrophic factor, cardiotrophin-1i, ciliary neurotrophic factor, ciliary neurotrophic factor receptor, cripto, cryptic, cytokine-induced neutrophil chemotactic factor 1, cytokine-induced neutrophil chemotactic factor 2a, cytokine-induced neutrophil chemotactic factor 2.beta., .beta. endothelial cell growth factor, endothelin 1, epidermal growth factor, epigen, epiregulin, epithelial-derived neutrophil attractant, fibroblast growth factor 4, fibroblast growth factor 5, fibroblast growth factor 6, fibroblast growth factor 7, fibroblast growth factor 8, fibroblast growth factor 8b, fibroblast growth factor 8c, fibroblast growth factor 9, fibroblast growth factor 10, fibroblast growth factor 11, fibroblast growth factor 12, fibroblast growth factor 13, fibroblast growth factor 16, fibroblast growth factor 17, fibroblast growth factor 19, fibroblast growth factor 20, fibroblast growth factor 21, fibroblast growth factor acidic, fibroblast growth factor basic, glial cell line-derived neurotrophic factor receptor aI, glial cell line-derived neurotrophic factor receptor ai2, growth related protein, growth related protein .alpha., growth related protein .beta., growth related protein .gamma., heparin binding epidermal growth factor, hepatocyte growth factor, hepatocyte growth factor receptor, hepatoma-derived growth factor, insulin-like growth factor I, insulin-like growth factor receptor, insulin-like growth factor II, insulin-like growth factor binding protein, keratinocyte growth factor, leukemia inhibitory factor, leukemia inhibitory factor receptor a.sup..about., nerve growth factor, nerve growth factor receptor, neuropoietin, neurotrophin-3, neurotrophin-4, oncostatin M (OSM), placenta growth factor, placenta growth factor 2, platelet-derived endothelial cell growth factor, platelet derived growth factor, platelet derived growth factor A chain, platelet derived growth factor AA, platelet derived growth factor AB, platelet derived growth factor B chain, platelet derived growth factor BB, platelet derived growth factor receptor a.sup..about., platelet derived growth factor receptor J3, pre-B cell growth stimulating factor, stem cell factor (SCF), stem cell factor receptor, TNF, TNFO, TNFI, TNF2, transforming growth factor .alpha., transforming growth factor .beta., transforming growth factor .beta.1, transforming growth factor .beta.1.2, transforming growth factor .beta.2, transforming growth factor .beta.3, transforming growth factor .beta.5, latent transforming growth factor .beta.1, transforming growth factor .beta. binding protein I, transforming growth factor .beta. binding protein II, transforming growth factor .beta. binding protein III, thymic stromal lymphopoietin (TSLP), tumor necrosis factor receptor type I, tumor necrosis factor receptor type II, urokinase-type plasminogen activator receptor, phospholipase-activating protein (PUP), insulin, lectin, ricin, prolactin, chorionic gonadotropin, follicle-stimulating hormone, thyroid-stimulating hormone, tissue plasminogen activator, IgG, IgE, IgM, IgA, and IgD, a-galactosidase, 03-galactosidase, DNAse, fetuin, luteinizing hormone, estrogen, albumin, lipoproteins, fetoprotein, transferrin, thrombopoietin, urokinase, integrin, thrombin, leptin, adalimumab, denosumab, etanercept, or a protein in Table 1. 6. The method according to claim 5 wherein a solution comprising an initial concentration of the therapeutic protein between about 0.1 mg/ml and about 5.0 mg/ml is adjusted to a pH value between about 5.0 and about 8.0 prior to contacting with the activated PSA. 7. The method of claim 5 comprising: a) a first step comprising adjusting the pH value of a solution comprising the therapeutic protein to a pH value between about 5.0 and about 8.0, wherein the therapeutic protein concentration is between about 0.3 mg/ml and about 3.0 mg/ml; b) a second step comprising oxidizing one or more carbohydrates on the therapeutic protein, wherein the oxidizing agent is added to the solution in the first step to result in a final concentration between about 10 .mu.M and about 1000 .mu.M, under conditions comprising a time period between about 0.1 minutes and about 5 hours; a temperature between about 2.degree. C. and about 37.degree. C.; in the presence or absence of light, and with or without stirring; c) a third step comprising contacting the therapeutic protein with a desired excess concentration of activated PSA, wherein the excess concentration is between about 1-fold molar excess and about 300-fold molar excess, under conditions comprising a time period between about 0.5 hours and about 24 hours, a temperature between about 2.degree. C. and about 37.degree. C.; in the presence or absence of light; and with or without stirring; d) a fourth step comprising adding a nucleophilic catalyst to the solution of the third step, wherein the nucleophilic catalyst is added to result in a final concentration between about 1 mM and about 50 mM, under conditions comprising a time period between about 0.1 minutes and about 30 minutes; a temperature between about 2.degree. C. and about 37.degree. C.; in the presence or absence of light, and with or without stirring; e) a fifth step wherein the therapeutic protein is incubated with the activated PSA and nucleophilic catalyst under conditions that allow conjugation of the activated PSA to one or more oxidized carbohydrates on the therapeutic protein, said conditions comprising a time period between about 0.5 hours and about 24 hours, a temperature between about 2.degree. C. and about 37.degree. C.; in the presence or absence of light, and with or without stirring; and f) a sixth step wherein the conjugating the PSA to the one or more oxidized carbohydrates of the therapeutic protein in the fifth step is stopped by the addition of a quenching agent selected from the group consisting of L-cysteine, methionine, glutathione, glycerol, Na.sub.2S.sub.2O.sub.5 (sodium meta bisulfite), tryptophane, tyrosine, histidine or derivatives thereof, kresol, imidazole, and combinations thereof; wherein the quenching agent is added to result in a final concentration of about 1 mM and about 100 mM, under conditions comprising a time period between about 5 minutes and about 120 minutes; a temperature between about 2.degree. C. and about 37.degree. C.; in the presence or absence of light, and with or without stirring. 8. The method of claim 5 comprising: a) a first step comprising adjusting the pH value of a solution comprising the therapeutic protein to a pH value of about 6.0, wherein the initial concentration of the therapeutic protein is about 1 mg/ml; b) a second step comprising oxidizing one or more carbohydrates on the therapeutic protein, wherein the oxidizing agent is added to the solution in the first step to result in a final concentration of about 400 M, under conditions comprising a time period of about 10 minutes, a temperature of about 22.degree. C., the absence of light and with stirring; c) a third step comprising contacting the therapeutic protein with a desired excess concentration of activated PSA, wherein the excess concentration is about 50-fold molar excess; under conditions comprising a time period of about 15 minutes, a temperature of about 22.degree. C., the absence of light and with stirring; d) a fourth step comprising adding a nucleophilic catalyst to the solution of the third step, wherein the nucleophilic catalyst is added to result in a final concentration of about 10 mM, under conditions comprising a time period of about 15 minutes, a temperature of about 22.degree. C., the absence of light and with stirring; e) a fifth step wherein the therapeutic protein is incubated with the activated PSA and nucleophilic catalyst under conditions that allow conjugation of the activated PSA to one or more oxidized carbohydrates on the therapeutic protein, said conditions comprising a time period of about 2 hours; a temperature of about 22.degree. C.; the absence of light; and with stirring; and f) a sixth step wherein the conjugating the PSA to the one or more oxidized carbohydrates of the therapeutic protein in the fifth step is stopped by the addition of L-cysteine; wherein the L-cysteine is added to result in a final concentration of about 10 mM, under conditions comprising a time period of about 60 minutes, a temperature of about 22.degree. C., the absence of light and with stirring. 9. The method according to claim 5 wherein the therapeutic protein has the same biological activity of FIX. 10. The method according to claim 5 wherein the therapeutic protein has the same biological activity of FVIIa. 11. The method according to claim 5 wherein the therapeutic protein has the same biological activity of FVIII. 12. The method according to claim 5 wherein the PSA comprises an activated aminooxy linker selected from the group consisting of: a) a 3-oxa-pentane-1,5-dioxyarnine linker of the formula: ##STR00018## b) a 3,6,9-trioxa-undecane-1,11-dioxyamine linker of the formula: ##STR00019## c) a 3,6,9,12,15-pentaoxa-heptadecane-1,17-dioxyamine linker of the formula: ##STR00020## wherein the PSA is oxidized by incubation with an oxidizing agent to form a terminal aldehyde group at the non-reducing end of the PSA. 13. The method according to claim 12 wherein the aminooxy linker is 3-oxa-pentane-1,5-dioxyamine. 14. A method of conjugating a PSA containing an active aminooxy group to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated PSA under conditions that allow conjugation; wherein the therapeutic protein has biological activity of Factor VIII (FVIII); wherein the PSA containing an active aminooxy group is prepared by a method comprising: a) incubating a solution comprising an oxidized PSA with an aminooxy linker comprising an active aminooxy group under conditions that allow the formation of a stable oxime linkage between the oxidized PSA and the activated aminooxy linker, said conditions comprising a time period between about 1 minute and about 24 hours; a temperature between about 2.degree. C. and about 10.degree. C.; in the presence or absence of light, and with or without stirring; thereby forming a PSA containing an active aminooxy group; and b) purifying the PSA containing an active aminooxy group by a method selected from the group consisting of chromatography, filtration, dialysis, and precipitation or combinations thereof, at a temperature between about 2.degree. C. and about 8.degree. C.; wherein said carbohydrate moiety is oxidized by incubation with a buffer comprising an oxidizing agent sodium periodate (NaIO.sub.4); wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the PSA; and wherein said oxime linkage formation is catalyzed by m-toluidine. 15. The method of claim 14 comprising: a) a first step comprising adjusting the pH value of a solution comprising the therapeutic protein to a pH value of about 6.0, wherein the initial concentration of the therapeutic protein is about 1 mg/ml; b) a second step comprising oxidizing one or more carbohydrates on the therapeutic protein, wherein NaIO.sub.4 is added to the solution in the first step to result in a final concentration of about 400 .mu.M, under conditions comprising a time period of about 10 minutes, a temperature of about 22.degree. C., the absence of light and with stirring; c) a third step comprising contacting the therapeutic protein with a desired excess concentration of activated PSA, wherein the excess concentration is about 50-fold molar excess; under conditions comprising a time period of about 15 minutes, a temperature of about 22.degree. C., the absence of light and with stirring; d) a fourth step comprising adding m-toluidine to the solution of the third step, wherein m-toluidine is added to result in a final concentration of about 10 mM, under conditions comprising a time period of about 15 minutes, a temperature of about 22.degree. C., the absence of light and with stirring; e) a fifth step wherein the therapeutic protein is incubated with the activated PSA and m-toluidine under conditions that allow conjugation of the activated PSA to one or more oxidized carbohydrates on the therapeutic protein, said conditions comprising a time period of about 2 hours; a temperature of about 22.degree. C.; the absence of light; and with stirring; and f) a sixth step wherein the conjugating the PSA to the one or more oxidized carbohydrates of the therapeutic protein in the fifth step is stopped by the addition of L-cysteine; wherein the L-cysteine is added to result in a final concentration of about 10 mM, under conditions comprising a time period of about 60 minutes, a temperature of about 22.degree. C., the absence of light and with stirring.

Details for Patent 10,576,160

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	10,576,160	2037-07-07
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	10,576,160	2037-07-07
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	10,576,160	2037-07-07
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	10,576,160	2037-07-07